John Evans, Beam Therapeutics CEO
With all hands on deck for lead sickle cell trial, Beam pulls back clinical plans for second base editing therapy
Almost a year after the FDA cleared their sickle cell disease program for a first-in-human trial, the base editing experts at Beam Therapeutics are still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
